Hyppigheden af CNS- blødninger i den 28- dages forsøgsperiode var henholdsvis 6 (0, 5%) og 5 (0, 4%) af de drotrecogin alfa (aktiveret) - behandlede og placebobehandlede patienter.
The incidence of CNS bleeds during the 28-day study period was 6 (0.5%) and 5 (0.4%) for drotrecogin alfa (activated)-treated and placebo-treated patients, respectively.